We provide insights into analyzing immune microenvironments and gene regulation features, indicating that both CPEB1 and COLEC12 are promising targets for immunotherapy of patients with diabetes who are diagnosed with BC. The gene discussed is COLEC12; the disease is diabetes mellitus.